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Abstract
Perhaps it is not surprising that in the critical care environment,
where lives are frequently on the line, off-label use of certain drugs
is relatively common. In general, there are two camps of opinion on
this type of utilization. One camp would suggest that potentially life
saving products cannot ethically be withheld from patients who
may benefit. The other camp would counter that it is inappropriate
to administer products if the risk/benefit ratio has not been clearly
defined in clinical trials. Off-label use of factor VII is debated in this
issue of Critical Care for a patient with uncontrolled nontraumatic
hemorrhage. Perhaps this product promotes additional discussion
given that its ability to control bleeding can be dramatic, yet its
costs and potential for complications high.
The scenario
A 49-year-old male has been managed in the intensive care
unit for 5 days after a large left diaphragmatic hernia repair
and is currently being weaned from mechanical ventilation.
He suddenly has significant hematemesis and becomes
hemodynamically unstable, with alteration to his coagulation.
You start to resuscitate him with fluid, blood and plasma, in
order to reverse the hemorrhagic shock and correct the
coagulopathy. An endoscopy reveals diffuse gastric erosions
but fails to stop the bleeding. He continues to be unstable
and surgical intervention is not an option. You are aware that
factor VIIa (FVIIa) has been used in acute traumatic
hemorrhage to stop bleeding. You wonder whether it has a
role to play in this type of patient.
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Pro: Potential benefit of recombinant FVIIa in the setting of coagulopathy associated with
acute hemorrhagic gastritis
Paola Pieri and Deborah M Stein
FVIIa (NovoSeven™) was developed by Novo Nordisk for use in
patients with congenital and acquired hemophilia and inhibitors
of factor VIII or IX. Since it was licensed in Europe in the 1990s
and in the USA in 1999 it has been utilized off-label in an
increasing number of nonhemophiliac patients with severe
bleeding, such as the patient described in the scenario above.
At present the precise role of FVIIa in treating life-threatening
hemorrhage has not been determined. However, numerous
studies have demonstrated benefit from off-label use.
Several case series have been published that describe
successful use of FVIIa in severely injured patients [1-4].
Additionally, in a recently published prospective randomized
placebo-controlled double blind trial [5], a reduction in
transfusion requirement was observed in trauma patients, as
was a decrease in overall morbidity and mortality when early
deaths were excluded from the analysis. There are numerous
other reports of successful use of FVIIa in the noninjured
patient with acute hemorrhage, such as that secondary to
esophageal varices, hemorrhagic pancreatitis, and hemor-
rhage occurring during cardiac surgery and liver trans-
plantation. Case reports of FVIIa use to treat patients with
resistant coagulopathies that developed in the intensive care
unit setting [1,6,7] have demonstrated efficacy in restoring
hemostasis, with subsequent survival largely dependent on
the underlying disease process. Prospective randomized
trials [8,9] have demonstrated successful use of FVIIa in
other patient populations, including those with acute
intracerebral hemorrhage and those undergoing elective
radical prostatectomy.Page 2 of 4
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With FVIIa use, the potential complications of pathological
and inappropriate thrombus formation is present but thought
to be low. A recently published US Food and Drug
Administration MedWatch database [10] described 151
complications associated with off-label use of FVIIa, the
majority occurring in trauma patients. However, MedWatch is
a database for voluntary reporting of observed complications,
and therefore the incidence of complications cannot be
calculated from it. Randomized studies [4,8] have found the
frequency of adverse events associated with administration of
FVIIa to be similar to those with placebo.
The patient presented above is a relatively healthy male, with
no assumed underlying significant medical conditions, who
undergoes an elective surgical procedure and subsequently
develops stress gastritis and life-threatening upper
gastrointestinal bleeding. Despite adequate and aggressive
resuscitation and medical management, he continues to
hemorrhage. Administration of FVIIa is certainly warranted in
this patient. Life-threatening hemorrhage and coagulopathy in
critical care patients carries significant morbidity and
mortality, with increased incidence of respiratory failure and
renal failure as well as multiple organ dysfunction. FVIIa has
efficacy in restoring hemostasis. Additionally, early administra-
tion — before the development of acidosis, hypothermia, and
subsequent additional coagulopathy — is likely to be more
efficacious. The risk for adverse events after FVIIa
administration is low, and in this case, although the patient is
in extremis, the potentially life-saving benefit of correcting the
patient’s coagulopathy and ceasing his hemorrhage clearly
takes precedent. Furthermore, the only other option for
arresting  hemorrhage in this patient in whom coagulopathy
cannot be reversed is a total gastrectomy, which is a procedure
with unacceptably high morbidity, both in the short and long
term. Therefore, off-label use of FVIIa in this setting is not only
warranted but also potentially beneficial and life saving.
Con: Recombinant FVIIa is not a cure for all bleeding
Sandro Scarpelini and Sandro Rizoli
We understand the clinical scenario and debate question as
whether one should administer a drug outside its licensed
indications (off-label) to treat a condition (upper gastro-
intestinal bleeding) without any evidence for the drug’s
efficacy and safety.
The first issue is the off-label use. After a single successful
report of off-label use of recombinant FVIIa (rFVIIa) in 1999,
many physicians began to experiment with this drug in
numerous bleeding situations [11]. Retrospective case
reports followed, almost invariably describing remarkable
results and further stimulating unlicensed use of rFVIIa [11].
More recently, many of the expectations raised by
retrospective reports are being revised as more balanced
results from randomized controlled trials (RCTs) are published
[8,9,11-15]. Particularly in gastrointestinal bleeding, RCTs
have contradicted many initial expectations and
demonstrated no clinical benefit of rFVIIa. In 2004 Romero-
Castro and coworkers [15] reported that all 10 patients with
cirrhosis and bleeding varices stopped bleeding after a single
bolus of rFVIIa. However, a subsequent 245-patient
European RCT conducted in this same population [13]
demonstrated that rFVIIa had no effect. The same occurred in
liver transplantation, in which a pilot six-patient study reported
100% efficacy in reducing bleeding but an 86-patient RCT
concluded that rFVIIa had no impact on perioperative blood
loss or need for blood transfusion [12]. One more caveat
comes from a multicenter survey of off-label use of rFVIIa in
American academic hospitals [16], which reported that only
52% of the patients stopped bleeding within 6 hours of rFVIIa
administration and 9% suffered adverse events. The latter
finding is worse than any case report or series and is
curiously similar to the 7% complication rate reported in a
399-patient RCT on intracerebral hemorrhage [9]. In
conclusion, off-label use might be inappropriate, wasteful,
and cause adverse effects more often than is currently
estimated.
The second issue is the lack of evidence. There are no
reports of rFVIIa use in diffuse gastric erosions, with the
arguable exception of a sketchy report [17]. In other
gastrointestinal bleeds, there are two RCTs (discussed above
and found no clinical benefit) and case reports/series in
Crohn’s disease, peptic ulcer, cancer/hematological
diseases, anticoagulant use, pancreatitis, and cirrhosis
[12,13]. The case reports/series are dismally small (two
patients with Crohn’s disease, one with peptic ulcer, one
receiving anticoagulant, and two with pancreatitis); case
reports are typically biased toward positive results, and the
diseases reported are different from the case in question. In
conclusion, there is no evidence suggesting rFVIIa might
benefit this patient.
A third consideration is that the moral/ethical implications of
administering a drug with unknown efficacy/safety, for
unlicensed indications. These implications should not be
neglected.
Finally, rFVIIa is an attractive proposition with potential to
change current practice [18]. There is reasonable evidence
to justify its off-label use in trauma, intracerebral hemorrhage,
cardiovascular surgery, large perioperative hemorrhage,
obstetrics, and anticoagulant-induced hemorrhage [5,8,11,
14]. However, there is also evidence disproving any benefit in
liver transplant, gastrointestinal bleeding (cirrhosis), liver
resection, and pelvic/acetabular surgery [11-13]. rFVIIa is notPage 3 of 4
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a panacea for all bleeding, and inappropriate use should be
as much a concern as not using it when it could be beneficial.
Since most indications for rFVIIa remain largely untested, we
should struggle to enroll patients into clinical trials that will
eventually define which patients do benefit from rFVIIa, rather
than promoting off-label use.
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Pro’s response: This patient cannot wait for the randomized controlled trial …
Paola Pieri and Deborah M Stein
Dr Rizoli presents accurate and important information
concerning the off-label use of rFVIIa. The clinical situation
presented, however, is more akin to the coagulopathy seen in
trauma, in which rFVIIa has demonstrated efficacy without
increased complications, than to a patient with a chronic
disease. Although some RCTs have shown no benefit in
patients with cirrhosis, varices, or transplants, this is not
necessarily relevant in the patient who was previously healthy
and developed life-threatening hemorrhage. Although rFVIIa
is certainly not a ‘panacea’, the potentially life-saving benefit
should outweigh concern that administration may fail, and
should not preclude its use.
Con’s response: Use of rFVIIa requires not only bleeding but also a reasonable expectation of
benefit
Sandro Scarpelini and Sandro Rizoli
Many believe that rFVIIa cures all bleeding, which is an
unsustainable conviction considering the current evidence.
RCTs have questioned the near perfect efficacy described by
many case reports, particularly in upper gastrointestinal
bleeding. The reasons to avoid rFVIIa in this patient are as
follows: it has not previously been used for a similar indication;
RCTs have shown no benefit in upper gastrointestinal bleeding
(cirrhotic); and use of rFVIIa as ‘last resort’ is futile [19].
The colleagues incorrectly stated that the trauma RCT [5]
demonstrated that rFVIIa decreases mortality in trauma.
rFVIIa is efficacious in many but not all circumstances. Apart
from ongoing bleeding, even off-label use demands
reasonable expectation of benefit. Ongoing bleeding and
reasonable expectation of benefit are mandatory even for
compassionate off-label use of rFVIIa.
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